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Abstract
Background—Existing evidence suggests that preoperative breast magnetic resonance imaging
(MRI) might not improve surgical outcomes in the general breast cancer population. To determine
if patients differentially benefit from breast MRI, we examined surgical outcomes—initial
mastectomy, reoperation, and final mastectomy rates—among patients grouped by histologic type.
Methods—We identified women diagnosed with early-stage breast cancer from 2004-2007 in the
SEER-Medicare dataset. We classified patients as having invasive ductal carcinoma (IDC),
invasive lobular carcinoma (ILC), mixed ductal/lobular carcinoma (IDLC) or other histologic
type. Medicare claims were used to identify breast MRI and definitive surgeries during the initial
surgical treatment episode. We used propensity score methods to account for the differential
likelihood of exposure to MRI.
Results—Of the 20,333 patients who met our inclusion criteria for this study, 12.2% had a
preoperative breast MRI. Patients with ILC as compared to other histologic groups were most
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likely to receive MRI (OR: 2.32; 95% CI: [2.02, 2.67]). In the propensity score adjusted analyses,
breast MRI was associated with an increased likelihood of an initial mastectomy for all patients
and among all histologic subgroups. Among patients with ILC, having a breast MRI was
associated with lower odds of a reoperation (OR: 0.59; 95% CI [0.40, 0.86]), and an equal
likelihood of a final mastectomy compared to similar patients without a breast MRI. Overall and
among patients with IDC and IDLC, breast MRI was not significantly associated with a likelihood
of a reoperation but was associated with greater odds of a final mastectomy.
Conclusion—Our study provides evidence in support of the targeted use of preoperative breast
MRI among patients with ILC to improve surgical planning; it does not provide evidence for the
routine use of breast MRI among all newly diagnosed breast cancer patients or among patients
with IDC.
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Introduction
Preoperative breast magnetic resonance imaging (MRI) is increasingly used to assess the
extent of breast tumor involvement and to inform surgical decision-making for older patients
with early-stage invasive breast cancer [1-4]. Despite its rapid adoption, there is a growing
body of evidence—including two randomized controlled trials (RCT) and several population
based studies—that suggests routine use of preoperative breast MRI results in more
extensive surgeries without clear evidence of clinical benefit such as improved surgical
outcomes [4-8]. Due to the lack of evidence demonstrating improved outcomes for patients
with preoperative breast MRI in the general breast cancer population, it is important to
examine and identify subpopulations of breast cancer patients in which the imaging
technique may be the most beneficial.
Because of the diffuse growth pattern of invasive lobular carcinoma (ILC), the second most
common histologic type of invasive breast cancer, it has been suggested that patients with
ILC may be likely more to benefit from preoperative breast MRI than women with invasive
ductal carcinoma (IDC) or other histologic types [9, 10]. As compared to women with IDC,
women with ILC are more prone to tumors not detected with mammography and ultrasound
examination [11, 12], to multifocal and multicentric breast involvement [13], and to have
higher reoperation rates [14-16]. Preoperative breast MRI has been found to be highly
sensitive in detecting lesions not seen using mammography or ultrasound among patients
with ILC [17]. However, only a few studies have examined the association between breast
MRI and surgical outcomes in women with ILC [5, 18-20]. These studies were limited in
that they were single institution studies [18-20] and an RCT from the United Kingdom[5]
with a small number of ILC patients from settings with distinct surgical treatment patterns,
health service resources, and insurance structures that may not be generalizable to the US
elderly population. A meta-analysis among ILC patients found that breast MRI was
associated with an increased likelihood of mastectomy but found only weak evidence that
breast MRI was associated with a lower likelihood of a reoperation [8]. Thus, additional
Fortune-Greeley et al. Page 2






















evidence is needed to determine the association between preoperative breast MRI and
surgical outcomes among patients with ILC in a sample comparable to the US elderly
population.
In this retrospective, population-based study, we used the Surveillance, Epidemiology, and
End Results (SEER)-Medicare linked dataset to assess the utilization and potential benefits
of preoperative breast MRI among newly diagnosed, elderly breast cancer patients by
histologic subgroup—IDC, ILC, and IDLC. To evaluate the benefit of breast MRI among
different histologic subgroups, we examined the association between preoperative breast
MRI and surgical outcomes—initial mastectomy, reoperation, and final mastectomy—for all
patients and within each histologic subgroup using propensity score methods.
Methods
Data
We conducted a retrospective study using the SEER-Medicare linked dataset, which is
derived from a consortium of population-based cancer registries across the United States
linked to Medicare administrative data and healthcare claims [21]. The SEER dataset
comprises 17 registries nationwide covers approximately 25% of the incident US cancer
population, and is nearly nationally representative [21]. The SEER data contain
demographic and incident cancer characteristics, including histology, grade, and stage.
Medicare covers payment for hospital services, physician services, some drug therapy, and
other medical services for more than 97% of Americans aged 65 and older [22]. The
Medicare claims provide information about the use and cost of health care services and co-
morbid health conditions. The National Cancer Institute (NCI) hospital file contains
hospital-level information, including staffing, structure, research network affiliation, and
information on accreditation [22].
Study Population
This study’s cohort was composed of women aged 66 or older diagnosed with their first,
unilateral, pathologically confirmed, stage I-IIB breast cancer (American Joint Committee
on Cancer [AJCC] sixth edition) between January 1, 2004 and December 31, 2007. To
capture each patient’s complete claims experience, we excluded women who were not
continuously enrolled in Medicare Part A and Part B or who were enrolled in a health
maintenance organization during the study period. Since this study focuses on the utilization
of preoperative breast MRI for surgical planning, we excluded women who received
neoadjuvant chemotherapy prior to surgery because breast MRI also is used to measure
tumor response to neoadjuvant chemotherapy [23-27]. In order to limit the cohort to women
in whom either breast conserving surgery or a mastectomy was likely to be considered, we
excluded patients with tumors larger than 5cm [28]. Women who were diagnosed with a
second primary cancer identified in SEER within 12 months of diagnosis were excluded in
order to avoid including claims for surgeries for second primaries in the initial surgical
treatment episode.
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To capture health services received by the patients, we examined all claims in Medicare
outpatient, inpatient, and physician claims files to identify breast cancer treatments and
surgical procedures during the initial surgical treatment episode. Treatments were identified
using the American Medical Association Current Procedural Terminology (CPT) and the
Healthcare Common Procedure Classification System (HCPCS) codes (for all codes used
see Table S1). We defined the initial surgical treatment episode as the time period beginning
with the first claim with a diagnosis code for a suspected breast disorder (e.g., lump or mass
in breast, or abnormal mammogram) 12 or fewer months prior to the SEER diagnosis. The
initial surgical treatment episode ended with the claim for a definitive surgery before a gap
in surgery of more than 90 days [29, 30]. We defined definitive surgery as either a partial
mastectomy or mastectomy and did not consider open biopsies or breast excisions to be
definitive surgeries [7, 31, 32]. Patients who had conflicting claims for a mastectomy and a
partial mastectomy on the same day or who did not have their first definitive surgery within
four months of their SEER-diagnosis were excluded.
Each patient’s tumor histology was classified using International Classification of Diseases
for Oncology (ICD-O-3) histologic codes for IDC (M-8500 or M-8521), ILC (M-8520),
mixed ductal/lobular carcinoma (IDLC) (M-8522-4), and other histology. Patients with
histologic codes that indicated pre-malignant or non-malignant lesions were excluded.
Detailed study population and inclusion/exclusion criteria can be found in Table S2.
Variables and Measures
Preoperative breast MRI receipt (our primary independent variable) and the three surgical
outcomes of interest—initial surgery, reoperation after partial mastectomy, and final surgery
(our dependent variables)—were identified by examining claims in the initial surgical
treatment episode. Patients were classified as having a preoperative breast MRI if they had a
claim for a breast MRI (CPT: 76093-94, 77058-59, HCPCS: C8903-C8908) before the date
of their initial surgery. The initial surgery was defined as the first claim for partial
mastectomy or mastectomy during the initial surgical treatment episode. For women with a
partial mastectomy as their initial surgery, a reoperation was defined as a claim for another
partial mastectomy or mastectomy after the date of the initial surgery but within the initial
surgical treatment episode. A sensitivity analysis defining a reoperation as a claim after the
initial surgery for an open breast excision, partial mastectomy, or mastectomy within the
initial surgical treatment episode produced equivalent results to our main analysis. The final
surgery was defined as the last definitive surgery in the initial surgical treatment episode.
We controlled for several other variables that have been previously shown to affect breast
cancer surgical decision-making in our analyses [33, 34]. We obtained tumor characteristics
from SEER including grade, tumor size, any node positivity, and hormone receptor status.
We used the NCI Comorbidity Index method to account for competing health demands and
risks of complications that may affect treatment selection [35]. Demographic characteristics
examined included age group at diagnosis, marital status, race, Hispanic ethnicity, and
SEER region. We included quartiles of the percentage of high school graduates in a given
zip code of residence and included a person-level indicator for Medicare state buy-in
coverage, which identified women who had their Medicare premiums and deductibles
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subsidized by the state during the study period owing to their financial status. We identified
the facility where the initial surgery took place and linked it to the NCI Hospital file to
identify whether or not the facility was a teaching hospital or a designated NCI Cancer
Center, and constructed a variable for whether or not the facility was affiliated with NCI
Cooperative Groups having breast cancer research portfolios [36]. We also included a
variable measuring breast cancer surgical volume. To construct this variable, we used the
number of breast cancer surgeries for each surgical facility from 2004-2009.
Statistical Analysis
We compared unadjusted baseline characteristics between patients grouped by histologic
type and breast MRI receipt using Pearson chi-squared tests for categorical variables and
Student’s t-tests for continuous variables. Because previous studies using the SEER-
Medicare dataset have shown that patients who receive a preoperative breast MRI differ
from women who do not on observed baseline characteristics such as age, race, and health
service area resources [1-4], we used propensity score methods to balance the groups of
women with and without breast MRI on measured covariates and to control for potential
confounders [37]. To estimate the treatment effect of breast MRI in the treated population
(i.e., those patients with breast MRI), we used standardized mortality ratio (SMR)
propensity score-based weighting [38]. Propensity scores for all patients and for each
histologic group were generated using multivariate logistic regression including the patient
and surgical facility characteristics described in the previous section [37]. Using SMR
weighting, women with breast MRI received a weight of 1 and women without breast MRI
were weighted with their propensity odds [38]. We assessed balance and the performance of
the model by examining the distribution of propensity scores and covariates between the two
groups (MRI vs. no MRI) and the change in standardized difference for each variable before
and after weighting [39, 40], and we determined the covariates were well balanced (Figure
S1). No patients from the Hawaii SEER region with ILC (n=14) or IDLC (n=18) had an
MRI, thus these patients had a zero propensity for breast MRI and were excluded in those
subgroup analyses. To generate our propensity score-weighted estimates, we used logistic
regression with robust standard errors. Z-test statistics and 95% confidence intervals were
used to examine the difference in the likelihood of our surgical outcomes between those
women with and without a breast MRI. Traditional multivariate models are presented in the
Supplementary Appendix (Tables S3-6) and were similar to our findings using propensity
scores.
Analyses were performed using Stata version 12.0 (Stata Corporation, College Station,
Texas). All tests were conducted using a minimum significance level of 0.05.
Results
Characteristics of the study population
Of the 20,333 patients who met inclusion criteria, 14,357 (70.6%) had IDC, 1,928 (9.5%)
had ILC, and 2,399 (11.8%) had IDLC (Table 1). Demographic, tumor, and surgical facility
characteristics significantly differed by histologic type for all variables. Notably, compared
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to other histologic types, women with ILC were more likely to have tumors that were larger
and hormone receptor positive.
Overall, 2,471 (12.2%) patients received a preoperative breast MRI. Breast MRI receipt
differed by histologic type with 10.8% of patients with IDC receiving a breast MRI
compared to 20.5% of patients with ILC (p-value: <0.001). The number of patients receiving
preoperative breast MRI increased over time for all patients and among all histologic types
(Figure 1). The subgroups of women with ILC and IDLC saw the greatest increase in use of
preoperative breast MRI. From 2004 to 2007, the proportion of patients with preoperative
breast MRI increased from 9.6% to 30.6% of those with ILC, from 8.9% to 27.3% of those
with IDLC, and from 4.6% to 18.5% of those with IDC.
In the multivariate logistic regression model predicting MRI receipt among all patients in
our sample, women with ILC or IDLC were more likely to have received a breast MRI than
women with IDC (Table S3). Women with a preoperative breast MRI were on average
younger, diagnosed more recently, and with fewer comorbidities overall and among all
histologic type subgroups. Women living in lower education areas had greater odds of
having an MRI, but having a state buy-in insurance supplement was associated with lower
odds of getting MRI. Women having their surgeries at facilities that were affiliated with
cooperative groups and a high surgical volume had significantly greater odds of receiving a
breast MRI.
Surgical Outcomes
Initial Mastectomy—Among the patients in our sample, 30.1% of patients (n=6,122) had
a mastectomy as their initial surgery (Table 2). Patients with ILC had the highest rate of
initial mastectomy (35.0%, n=675), and patients with IDLC had the lowest rate (28.7%,
n=688). After propensity score adjustment (Figure 2), having a preoperative breast MRI was
significantly associated with greater odds of an initial mastectomy for all patients (odds ratio
[OR] 1.33; 95% confidence interval [CI] [1.19, 1.48]) and among all histologic types
subgroups (IDC OR:1.21; 95% CI [1.07, 1.38]; ILC OR: 1.48; 95% CI [1.10, 2.00]; IDLC
OR: 1.98; 95% CI [1.50, 2.62]).
Reoperations—Overall, 20.6% (n=2,929) of women in our sample had an additional
reoperation after having an initial breast conserving surgery. Reoperations were most
common in women with ILC, (28.3%, n=355) and least common in women with IDC
(19.1%, n=1,920). After propensity score adjustment, having a breast MRI was associated
with lower odds of having a reoperation among women with ILC (OR: 0.59; 95% CI [0.40,
0.86]), but was not significantly associated with reoperations among other histologic
subgroups.
Final Mastectomy—Of all patients in our sample, 35.5% (n=7,224) had a mastectomy as
their only or final surgery. Among histologic type subgroups, patients with ILC had the
highest percentage of final mastectomies (43.5%, n=839) and patients with IDC had the
lowest (34.7%, n=4,984). After propensity score adjustment, breast MRI receipt was
associated with increased odds of a final mastectomy among all patients (OR: 1.20; 95% CI
[1.08, 1.33]) and among patients with IDC (OR: 1.21; 95% CI [1.07, 1.37]) and IDLC (1.43;
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95% CI [1.10, 1.85]). Having a breast MRI was not significantly associated with a final
mastectomy in the subgroup of patients with ILC.
Discussion
In this large, population-based study, we found that the association between breast MRI and
surgical outcomes differed by histologic subgroup. In particular, among women with ILC,
breast MRI was associated with a reduced likelihood of a reoperation and an equal
likelihood of a final mastectomy compared to similar patients without a breast MRI. We did
not find breast MRI to be associated with improved surgical outcomes overall and among
IDC patients and IDLC patients; In fact, in these groups of patients, preoperative breast MRI
was significantly associated with an increased likelihood of more extensive surgeries—
including both initial and final mastectomy—but not with reoperations.
This is the largest study of breast MRI among ILC patients (n=1,928) to date. Previous
research examining the association between breast MRI and surgical outcomes for ILC
patients found conflicting results regarding the benefit of breast MRI [5, 8, 18-20]. Our
findings are similar to a meta-analysis among ILC patients which found that breast MRI was
significantly associated with an increased likelihood of an initial mastectomy and weakly
associated with a lower likelihood of a reoperation [8]. Our results differed from the meta-
analysis in that the meta-analysis reported that preoperative breast MRI was associated with
an increased likelihood of a final mastectomy whereas we found that ILC patients with
breast MRI were no more likely to have a final mastectomy than those ILC women who did
not receive a preoperative breast MRI. Our results may differ because the included studies
were single institution studies [18-20] and one RCT [5] which included only a small number
of patients with ILC. Furthermore, these studies reflect surgical practices from single
institutions or in the United Kingdom, where breast cancer treatment patterns, decision-
making factors, health service/insurance structures, and fiscal considerations may be
different than and not generalizable to the US elderly population.
Breast MRI may be most useful in women with ILC because the biological and clinical
features of ILC make it difficult to detect by screening and to determine the extent of
disease. Women with ILC are more likely to be inadequately imaged with conventional
assessment that includes mammography and sonography [11, 12], which in turn can
complicate surgical planning and lead to suboptimal surgical outcomes for patients with
ILC. We found that patients with ILC received more intensive surgical treatment than
patients with other subtypes and were more likely to have an initial mastectomy (35% vs
30%), a reoperation (28% vs 21%), and a final mastectomy (44% vs 36%) compared to all
breast cancer patients. Thus, particularly as the incidence of ILC is increasing in older
women [9], it is promising that breast MRI may be beneficial to optimize surgical planning
and reduce reoperations in this group of women without compromising the likelihood of
breast conservation.
Our results contribute to the growing body of literature documenting that routine breast MRI
is associated with an increased likelihood of a mastectomy [4-6, 8, 41, 42] and not
associated with a reduction in reoperations [5-8, 41-47] among all breast cancer patients.
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The results from our analyses among patients with IDC and IDLC provide novel evidence
about the association between breast MRI and surgical outcomes in these histologic type
subgroups.
Since preoperative breast MRI was not associated with improved surgical outcomes among
older women with IDC and IDLC, it is important to assess the potential consequences of the
increasing use of preoperative breast MRI in the general population. Concern exists that
breast MRI may overestimate tumor size, resulting in a more extensive surgery than may be
required to obtain negative margins. In our study, preoperative breast MRI was associated
with an increased likelihood of an initial mastectomy and an increased likelihood of a final
mastectomy overall and in patients with IDC or IDLC without a reduction in the likelihood
of a reoperation. The association between breast MRI and mastectomies could be concerning
if women are electing or surgeons are recommending more extensive surgery based on MRI
findings that overestimate the true extent of disease or could be adequately managed by
radiation and systemic therapy [48]. Additionally, preoperative breast MRI may contribute
to greater use of additional diagnostic procedures which carry their own potential
morbidities. Studies have found that breast MRI may be associated with more downstream
imaging such as follow-up ultrasounds, more biopsies, and treatment delay [44, 49, 50]. The
increased morbidity that may arise from the downstream consequences of breast MRI in
absence of clear clinical benefit is troubling as more breast cancer patients are having
comparatively favorable prognoses, and many clinicians are focusing on reducing treatment
burden and morbidity [51].
This study provides evidence to support the targeted use of preoperative breast MRI among
patients with ILC. Given that women with ILC were more likely to have a preoperative
breast MRI (OR: 2.32; 95% CI: [2.02, 2.67]) than women with other histologic types, some
providers or surgical facilities may already be using ILC as section criteria to optimize the
benefit of preoperative breast MRI. We did not find evidence to support routine use of
preoperative breast MRI among all patients; however, the rapid increase in use of the
imaging technique from 2004 to 2007 and the observed variation in preoperative breast MRI
by provider and SEER region suggests that it is unlikely that breast MRI is being utilized
solely among select subpopulations, such as women with ILC or women inadequately
imaged using conventional assessment.
Our study is limited in several aspects. Like all observational studies, we were unable to
control for unmeasured confounding. Using propensity score methods, we successfully
balanced women with and without breast MRI on observed clinical, sociodemographic, and
surgical facility variables; however, we were unable to balance the women on unobserved
characteristics that may be associated with breast MRI and our outcomes, and thus we are
concerned that our models are underspecified due to variables not available in our dataset.
For example, the clinical rationale for why the MRI was ordered is unknown, and we are
unable differentiate women who received an MRI as a part of routine preoperative work-up
from those women who received an MRI because their tumors were inadequately imaged
using conventional assessment. The specific MRI results for each patient are also unknown,
and we are unable to verify the extent to which the MRI results changed surgical decision-
making using claims data. These unknown factors may be associated with breast MRI
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receipt and also may influence surgical outcomes. Also, we were unable to control for
women who chose to have an initial mastectomy instead of breast conserving surgery based
on their preferences. Other mastectomy and reoperation risk factors not available in the
SEER-Medicare data included information about multifocal disease, mammographic density
and micro-calcifications and surgeon experience and practice style [7, 34, 52-54]. We were,
nevertheless, able to control for tumor size, grade and histology, age, advanced stage,
hormone receptor negative status, which have also been reported as mastectomy and or
reoperation risk factors [52].
As new and advanced imaging modalities such as breast MRI are introduced into clinical
practice, it is important to generate evidence about their appropriate use and to inform their
dissemination into practice. Our study provides evidence in support of the targeted use of
preoperative breast MRI among patients with ILC to improve surgical planning. Our study
also adds to the growing body of literature documenting that routine breast MRI among all
breast cancer patients is associated with an increased likelihood of a mastectomy and not
associated with a reduction in reoperations among the majority of breast cancer patients in
whom it is used. Future research should examine the association between preoperative breast
MRI and long-term outcomes such as breast cancer recurrence and survival, particularly
among patients with ILC.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 2. Association between preoperative breast MRI and the odds of surgical outcomes by
histologic subgroups adjusted using propensity scores
Estimated propensity score adjusted odds ratio of patients with preoperative breast MRI
compared to patients with no MRI is represented by a solid circle (horizontal line represents
95% confidence interval) by surgical outcome and by histologic subgroup. No patients from
the Hawaii SEER region with ILC (n=14) or IDLC (n=18) had an MRI, thus these patients
had a zero propensity for breast MRI and were excluded in those subgroup analyses.
MRI, Magnetic Resonance Imaging
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Table 1
Demographic and cancer characteristics of sample
All patients Ductal Lobular
Mixed ductal/
lobular p-value
N= 20,332 N=14,357 N=1,928 N=2,398
N (%) N (%) N (%) N (%)
Preoperative breast MRI 2,471 (12.2%) 1,557 (10.8%) 396 (20.5%) 390 (16.3%) <0.001
Histology <0.001
  Ductal 14,357 (70.6%) 14,357 (100%) - -
  Lobular 1,928 (9.5%) - 1,928 (100%) -
  Mixed ductal/lobular 2,398 (11.8%) - - 2,398 (100%)
  Other 1,649 (8.1%) - - -
Tumor Size <0.001
  T < 2cm 14,566 (71.6%) 10,500 (73.1%) 1,192 (61.8%) 1,671 (69.7%)
  T > 2cm, < 5cm 5,766 (28.4%) 3,857 (26.9%) 736 (38.2%) 727 (30.3%)
Tumor grade <0.001
  Well differentiated 5,221 (25.7%) 3,315 (23.1%) 478 (24.8%) 651 (27.1%)
  Moderately differentiated 8,917 (43.9%) 6,399 (44.6%) 898 (46.6%) 1,177 (49.1%)
  Poorly differentiated 5,140 (25.3%) 4,297 (29.9%) 185 (9.6%) 446 (18.6%)
  Grade unknown 1,054 (5.2%) 346 (2.4%) 367 (19.0%) 124 (5.2%)
Hormone Receptor Status <0.001
  Positive 15,965 (78.5%) 10,919 (76.1%) 1,697 (88.0%) 2,082 (86.8%)
  Negative 2,705 (13.3%) 2,282 (15.9%) 64 (3.3%) 151 (6.3%)
  Unknown 1,662 (8.2%) 1,156 (8.1%) 167 (8.7%) 165 (6.9%)
Node positivity 4,360 (21.4%) 3,232 (22.5%) 435 (22.6%) 547 (22.8%) <0.001
NCI Comorbidity Index 0.001
  0 12,996 (63.9%) 9,068 (63.2%) 1,294 (67.1%) 1,597 (66.6%)
  Between 0 and 1 5,648 (27.8%) 4,058 (28.3%) 495 (25.7%) 628 (26.2%)
  Between 1 and 2 1,688 (8.3%) 1,231 (8.6%) 139 (7.2%) 173 (7.2%)
Age at diagnosis <0.001
  65 to 69 4,215 (20.7%) 3,060 (21.3%) 357 (18.5%) 525 (21.9%)
  70 to 74 4,999 (24.6%) 3,561 (24.8%) 472 (24.5%) 572 (23.9%)
  75 to 79 4,899 (24.1%) 3,424 (23.8%) 463 (24.0%) 594 (24.8%)
  80 to 84 3,791 (18.6%) 2,638 (18.4%) 382 (19.8%) 430 (17.9%)
  85 and older 2,428 (11.9%) 1,674 (11.7%) 254 (13.2%) 277 (11.6%)
Married 9,312 (45.8%) 6,590 (45.9%) 899 (46.6%) 1,123 (46.8%) 0.05
State buy-in coverage <0.001
  No 18,144 (89.2%) 12,793 (89.1%) 1,761 (91.3%) 2,162 (90.2%)
  Yes 2,188 (10.8%) 1,564 (10.9%) 167 (8.7%) 236 (9.8%)
Race <0.001
  White 17,652 (86.8%) 12,400 (86.4%) 1,721 (89.3%) 2,134 (89%)
  Non-white 2,680 (13.2%) 1,957 (13.6%) 207 (10.7%) 264 (11%)
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All patients Ductal Lobular
Mixed ductal/
lobular p-value
N= 20,332 N=14,357 N=1,928 N=2,398
N (%) N (%) N (%) N (%)
Co-operative group affiliation
 of surgical facility 10,383 (51.1%) 7,214 (50.2%) 1,023 (53.1%) 1,352 (56.4%) <0.001
NCI affiliation of surgical
 facility 1,042 (5.1%) 701 (4.9%) 91 (4.7%) 189 (7.9%) <0.001
Surgical facility a teaching
  hospital or affiliated one 10,603 (52.1%) 7,339 (51.1%) 1,041 (54.0%) 1,385 (57.8%) <0.001
Surgical volume of surgical facility <0.001
  Low volume 9,944 (48.9%) 7,170 (49.9%) 910 (47.2%) 1,010 (42.1%)
  High volume 10,388 (51.1%) 7,187 (50.1%) 1,018 (52.8%) 1,388 (57.9%)
Zip code proportion with at least
 high school education (quartiles) <0.001
  Low education 5,055 (24.9%) 3,490 (24.3%) 496 (25.7%) 699 (29.1%)
  Low-medium education 4,890 (24.1%) 3,478 (24.2%) 467 (24.2%) 558 (23.3%)
  Medium-high education 4,793 (23.6%) 3,378 (23.5%) 448 (23.2%) 556 (23.2%)
  High education 4,776 (23.5%) 3,443 (24.0%) 439 (22.8%) 482 (20.1%)
  Unknown education 818 (4.0%) 568 (4%) 78 (4.0%) 103 (4.3%)
Year of diagnosis <0.001
  2004 5,010 (24.6%) 3,496 (24.4%) 437 (22.7%) 637 (26.6%)
  2005 4,837 (23.8%) 3,381 (23.5%) 461 (23.9%) 572 (23.9%)
  2006 5,194 (25.5%) 3,655 (25.5%) 503 (26.1%) 617 (25.7%)
  2007 5,291 (26.0%) 3,825 (26.6%) 527 (27.3%) 572 (23.9%)
SEER Region <0.001
  California registries 6,647 (32.7%) 4,725 (32.9%) 595 (30.9%) 810 (33.8%)
  Northeast registries 4,724 (23.2%) 3,187 (22.2%) 490 (25.4%) 704 (29.4%)
  Georgia 680 (3.3%) 499 (3.5%) 63 (3.3%) 73 (3.0%)
  Detroit 1,413 (6.9%) 993 (6.9%) 141 (7.3%) 157 (6.5%)
  Iowa 1,439 (7.1%) 1,059 (7.4%) 145 (7.5%) 117 (4.9%)
  New Mexico 431 (2.1%) 291 (2.0%) 48 (2.5%) 51 (2.1%)
  Seattle 1,207 (5.9%) 866 (6.0%) 131 (6.8%) 129 (5.4%)
  Utah 551 (2.7%) 394 (2.7%) 35 (1.8%) 69 (2.9%)
  Kentucky 1,564 (7.7%) 1,141 (7.9%) 130 (6.7%) 145 (6.0%)
  Louisiana 1,423 (7.0%) 1,005 (7.0%) 136 (7.1%) 125 (5.2%)
  Hawaii 253 (1.2%) 198 (1.4%) 14 (0.7%) 18 (0.8%)
MRI, Magnetic Resonance Imaging; SEER, Surveillance, Epidemiology and End Results; NCI, National Cancer Institute.
†
NCI Cooperative Groups having breast cancer research portfolios
P-values by ANOVA for continuous variables and chi2 test for binary / categorical variables. P-values were based on the differences between the
four histologic groups: Ductal, Lobular, Mixed ductal/lobular and other.
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